Copyright Reports & Markets. All rights reserved.

Global Antibody-drug Conjugates Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Antibody-drug Conjugates Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Antibody-drug Conjugates Market Size Growth Rate by Product
      • 1.4.2 Adcetris
      • 1.4.3 Kadcyla
    • 1.5 Market by End User
      • 1.5.1 Global Antibody-drug Conjugates Market Size Growth Rate by End User
      • 1.5.2 Breast Cancer
      • 1.5.3 Lymphoma
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Antibody-drug Conjugates Market Size
      • 2.1.1 Global Antibody-drug Conjugates Revenue 2014-2025
      • 2.1.2 Global Antibody-drug Conjugates Sales 2014-2025
    • 2.2 Antibody-drug Conjugates Growth Rate by Regions
      • 2.2.1 Global Antibody-drug Conjugates Sales by Regions
      • 2.2.2 Global Antibody-drug Conjugates Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Antibody-drug Conjugates Sales by Manufacturers
      • 3.1.1 Antibody-drug Conjugates Sales by Manufacturers
      • 3.1.2 Antibody-drug Conjugates Sales Market Share by Manufacturers
      • 3.1.3 Global Antibody-drug Conjugates Market Concentration Ratio (CR5 and HHI)
    • 3.2 Antibody-drug Conjugates Revenue by Manufacturers
      • 3.2.1 Antibody-drug Conjugates Revenue by Manufacturers (2014-2019)
      • 3.2.2 Antibody-drug Conjugates Revenue Share by Manufacturers (2014-2019)
    • 3.3 Antibody-drug Conjugates Price by Manufacturers
    • 3.4 Antibody-drug Conjugates Manufacturing Base Distribution, Product Types
      • 3.4.1 Antibody-drug Conjugates Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Antibody-drug Conjugates Product Type
      • 3.4.3 Date of International Manufacturers Enter into Antibody-drug Conjugates Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Antibody-drug Conjugates Sales by Product
    • 4.2 Global Antibody-drug Conjugates Revenue by Product
    • 4.3 Antibody-drug Conjugates Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Antibody-drug Conjugates Breakdown Data by End User

    6 North America

    • 6.1 North America Antibody-drug Conjugates by Countries
      • 6.1.1 North America Antibody-drug Conjugates Sales by Countries
      • 6.1.2 North America Antibody-drug Conjugates Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Antibody-drug Conjugates by Product
    • 6.3 North America Antibody-drug Conjugates by End User

    7 Europe

    • 7.1 Europe Antibody-drug Conjugates by Countries
      • 7.1.1 Europe Antibody-drug Conjugates Sales by Countries
      • 7.1.2 Europe Antibody-drug Conjugates Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Antibody-drug Conjugates by Product
    • 7.3 Europe Antibody-drug Conjugates by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Antibody-drug Conjugates by Countries
      • 8.1.1 Asia Pacific Antibody-drug Conjugates Sales by Countries
      • 8.1.2 Asia Pacific Antibody-drug Conjugates Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Antibody-drug Conjugates by Product
    • 8.3 Asia Pacific Antibody-drug Conjugates by End User

    9 Central & South America

    • 9.1 Central & South America Antibody-drug Conjugates by Countries
      • 9.1.1 Central & South America Antibody-drug Conjugates Sales by Countries
      • 9.1.2 Central & South America Antibody-drug Conjugates Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Antibody-drug Conjugates by Product
    • 9.3 Central & South America Antibody-drug Conjugates by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Antibody-drug Conjugates by Countries
      • 10.1.1 Middle East and Africa Antibody-drug Conjugates Sales by Countries
      • 10.1.2 Middle East and Africa Antibody-drug Conjugates Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Antibody-drug Conjugates by Product
    • 10.3 Middle East and Africa Antibody-drug Conjugates by End User

    11 Company Profiles

    • 11.1 ImmunoGen
      • 11.1.1 ImmunoGen Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 ImmunoGen Antibody-drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 ImmunoGen Antibody-drug Conjugates Products Offered
      • 11.1.5 ImmunoGen Recent Development
    • 11.2 Seattle Genetics
      • 11.2.1 Seattle Genetics Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Seattle Genetics Antibody-drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Seattle Genetics Antibody-drug Conjugates Products Offered
      • 11.2.5 Seattle Genetics Recent Development
    • 11.3 Roche
      • 11.3.1 Roche Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Roche Antibody-drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Roche Antibody-drug Conjugates Products Offered
      • 11.3.5 Roche Recent Development
    • 11.4 Takeda
      • 11.4.1 Takeda Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Takeda Antibody-drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Takeda Antibody-drug Conjugates Products Offered
      • 11.4.5 Takeda Recent Development

    12 Future Forecast

    • 12.1 Antibody-drug Conjugates Market Forecast by Regions
      • 12.1.1 Global Antibody-drug Conjugates Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Antibody-drug Conjugates Revenue Forecast by Regions 2019-2025
    • 12.2 Antibody-drug Conjugates Market Forecast by Product
      • 12.2.1 Global Antibody-drug Conjugates Sales Forecast by Product 2019-2025
      • 12.2.2 Global Antibody-drug Conjugates Revenue Forecast by Product 2019-2025
    • 12.3 Antibody-drug Conjugates Market Forecast by End User
    • 12.4 North America Antibody-drug Conjugates Forecast
    • 12.5 Europe Antibody-drug Conjugates Forecast
    • 12.6 Asia Pacific Antibody-drug Conjugates Forecast
    • 12.7 Central & South America Antibody-drug Conjugates Forecast
    • 12.8 Middle East and Africa Antibody-drug Conjugates Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Antibody-drug Conjugates Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
      North America ranks the top in terms of global market size of Antibody Drug Conjugate, it consists of 59.12% of the international market in 2016. Europe comes the second, with 27.70% of the global market. Asia Pacific consists of 6.54%of the Antibody Drug Conjugate market in the same year.
      Takeda ranks the first in terms of revenue share in Global market of Antibody Drug Conjugate, occupies 54.17% of market share in 2016; While, Roche, with a market share of 35.11%, comes the second; The other companies consist of approximately 10.72% of the global market in 2016.
      The global Antibody-drug Conjugates market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Antibody-drug Conjugates market based on company, product type, end user and key regions.

      This report studies the global market size of Antibody-drug Conjugates in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Antibody-drug Conjugates in these regions.
      This research report categorizes the global Antibody-drug Conjugates market by top players/brands, region, type and end user. This report also studies the global Antibody-drug Conjugates market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      ImmunoGen
      Seattle Genetics
      Roche
      Takeda

      Market size by Product
      Adcetris
      Kadcyla
      Market size by End User
      Breast Cancer
      Lymphoma

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Antibody-drug Conjugates market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Antibody-drug Conjugates market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Antibody-drug Conjugates companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Antibody-drug Conjugates submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Antibody-drug Conjugates are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (Kg). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Antibody-drug Conjugates market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now